This technology could be used in combinationto monitor the effectiveness of a particular therapy. Thus, this technologypermits early detection of amyloid lesions.

About

Summary Researchers at NYU have developed a method fordiagnosing Alzheimer's disease by early detection of amyloid plaques in-vivousing magnetic resonance imaging. This method relies on using an Aß-1-40peptide bound to a contrast agent which, upon injection, binds selectively toAß. This material is injected systemically with mannitol which acts totransiently open the blood-brain barrier such that pre-Aß deposits and amyloidplaques can be visualized under MRI conditions routinely used clinically. This technology has beendemonstrated in a transgenic mouse model for Alzheimer's disease. Followinginjection of mice with the contrast agent bound to Aß1-40 and mannitol, MRIdetected the presence of both amyloid and pre-amyloid plaques. The injectedmice showed good correlation with the corresponding immunohistochemicallystained brain sections for amyloid.  

Register for free for full unlimited access to all innovation profiles on LEO

  • Discover articles from some of the world’s brightest minds, or share your thoughts and add one yourself
  • Connect with like-minded individuals and forge valuable relationships and collaboration partners
  • Innovate together, promote your expertise, or showcase your innovations